AU2007223057B2 - Ocular therapy using sirtuin-activating agents - Google Patents

Ocular therapy using sirtuin-activating agents Download PDF

Info

Publication number
AU2007223057B2
AU2007223057B2 AU2007223057A AU2007223057A AU2007223057B2 AU 2007223057 B2 AU2007223057 B2 AU 2007223057B2 AU 2007223057 A AU2007223057 A AU 2007223057A AU 2007223057 A AU2007223057 A AU 2007223057A AU 2007223057 B2 AU2007223057 B2 AU 2007223057B2
Authority
AU
Australia
Prior art keywords
implant
sirtuin
activating agent
eye
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007223057A
Other languages
English (en)
Other versions
AU2007223057A1 (en
Inventor
John E. Donello
Fabien J. Schweighoffer
Elizabeth Wolde Mussie
Rong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2007223057A1 publication Critical patent/AU2007223057A1/en
Application granted granted Critical
Publication of AU2007223057B2 publication Critical patent/AU2007223057B2/en
Priority to AU2011239238A priority Critical patent/AU2011239238B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
AU2007223057A 2006-03-08 2007-03-07 Ocular therapy using sirtuin-activating agents Ceased AU2007223057B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011239238A AU2011239238B2 (en) 2006-03-08 2011-10-20 Ocular therapy using sirtuin-activating agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/371,117 US20070212395A1 (en) 2006-03-08 2006-03-08 Ocular therapy using sirtuin-activating agents
US11/371,117 2006-03-08
PCT/US2007/063454 WO2007103960A1 (en) 2006-03-08 2007-03-07 Ocular therapy using sirtuin-activating agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011239238A Division AU2011239238B2 (en) 2006-03-08 2011-10-20 Ocular therapy using sirtuin-activating agents

Publications (2)

Publication Number Publication Date
AU2007223057A1 AU2007223057A1 (en) 2007-09-13
AU2007223057B2 true AU2007223057B2 (en) 2011-07-21

Family

ID=38230138

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007223057A Ceased AU2007223057B2 (en) 2006-03-08 2007-03-07 Ocular therapy using sirtuin-activating agents

Country Status (7)

Country Link
US (1) US20070212395A1 (enExample)
EP (1) EP1991205A1 (enExample)
JP (2) JP2009529538A (enExample)
AU (1) AU2007223057B2 (enExample)
BR (1) BRPI0708622A2 (enExample)
CA (1) CA2643903C (enExample)
WO (1) WO2007103960A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20060062690A1 (en) * 2004-08-17 2006-03-23 Polymer Technology Systems, Inc. Apparatus and method of manufacturing bodily fluid test strip
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
EP2197434A4 (en) * 2007-09-20 2011-08-10 Resveratrol Partners Llc Compositions Containing Resveratrol for Modulating Genetic Product Concentration or Activity
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2276439A4 (en) 2008-05-12 2013-11-27 Univ Utah Res Found DEVICE AND CORRESPONDING METHODS FOR INTRAOCULAR MEDICAMENT ADMINISTRATION
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
WO2012071476A2 (en) 2010-11-24 2012-05-31 David Haffner Drug eluting ocular implant
EP2470157A1 (en) * 2009-08-24 2012-07-04 The Board of Governors for Higher Education, State of Rhode Island and Providence Plantations Hot-melt extruded compositions containing plant-derived phenolic materials and processes for the preparation thereof
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CA2819108A1 (en) * 2010-12-15 2012-06-21 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2013058838A2 (en) * 2011-06-10 2013-04-25 Wong Vernon G Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer
JP5848042B2 (ja) 2011-06-29 2016-01-27 株式会社ロッテ 眼疲労抑制組成物及びそれを含む飲食品
ES2428665B1 (es) * 2012-05-04 2014-10-01 Universidad De Valladolid Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
CN105188666A (zh) 2013-04-01 2015-12-23 阿勒根公司 用于持续的眼内释放的微球药物递送系统
TR201802759T4 (tr) 2013-10-31 2018-03-21 Allergan Inc Prostamid içeren intraoküler implantlar ve kullanım yöntemleri.
JP6236304B2 (ja) * 2013-12-04 2017-11-22 ライオン株式会社 涙液分泌促進剤
EP3148491B1 (en) 2014-05-29 2020-07-01 Glaukos Corporation Implants with controlled drug delivery features and manufacturing method for said implants
TWI658828B (zh) * 2014-10-31 2019-05-11 中國醫藥大學 用於舒緩及減輕近視之醫藥組合物及其製備方法與用途
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
LT3416654T (lt) 2016-02-18 2022-01-10 Invirsa, Inc. 5’-adenozindifosfato ribozės (adpr) medicininis panaudojimas
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
ES2949441T3 (es) 2018-03-27 2023-09-28 Invirsa Inc Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR)
WO2020115765A1 (en) 2018-12-05 2020-06-11 Celagenex Research (India) Pvt. Ltd. Novel synergistic composition comprising sirt1 and ampk activators for treating metabolic syndrome
CN117529308A (zh) * 2019-12-19 2024-02-06 鹏达特生物科学公司 交联的pla基共聚物
CN114917209B (zh) * 2022-05-23 2024-01-23 广西大学 白皮杉醇在抗弓形虫感染的应用
WO2024180472A1 (en) * 2023-02-28 2024-09-06 Alcon Inc. Ocular inserts

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077176A1 (en) * 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963025A (en) * 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
ES2232005T3 (es) * 1997-08-11 2005-05-16 Allergan, Inc. Dispositivo de implante biodegradable esteril que contiene retinoide con biocompatibilidad mejorada y metodo de preparacion.
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6699493B2 (en) * 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
AU2004253579B2 (en) * 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
BRPI0510485A (pt) * 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
ES2663226T3 (es) * 2004-06-04 2018-04-11 Washington University Procedimientos y composiciones para tratar neuropatías
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
CA2609549A1 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077176A1 (en) * 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof

Also Published As

Publication number Publication date
CA2643903A1 (en) 2007-09-13
AU2007223057A1 (en) 2007-09-13
JP2009529538A (ja) 2009-08-20
EP1991205A1 (en) 2008-11-19
US20070212395A1 (en) 2007-09-13
BRPI0708622A2 (pt) 2011-06-07
CA2643903C (en) 2016-06-28
JP2014028822A (ja) 2014-02-13
WO2007103960A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
AU2007223057B2 (en) Ocular therapy using sirtuin-activating agents
JP5826872B2 (ja) 眼内使用のための環状脂質インプラントの製造法
JP5696121B2 (ja) α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント
US8529927B2 (en) Alpha-2 agonist polymeric drug delivery systems
US20050271705A1 (en) Retinoid-containing sustained release intraocular drug delivery system and related methods
AU2016231616A1 (en) Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2005110367A2 (en) Sustained release intraocular implants and methods for preventing retinal dysfunction
JP2007535564A (ja) 抗興奮毒性剤持続放出眼内インプラントおよび関連方法
AU2020203616B2 (en) Processes for making cyclic lipid implants for intraocular use
AU2011239238B2 (en) Ocular therapy using sirtuin-activating agents
AU2018203995B2 (en) Processes for making cyclic lipid implants for intraocular use
HK1253728B (en) Processes for making cyclic lipid implants for intraocular use
HK1193772A (en) Processes for making cyclic lipid implants for intraocular use
HK1193772B (en) Processes for making cyclic lipid implants for intraocular use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired